Summary
StartUp Health community member Manuel Kraus, Co-founder of MindAhead, based in Germany, shares details on the company’s digital behavioral therapy aimed at improving the quality of life and slowing cognitive decline in people with mild cognitive impairment and early dementia. Their therapy focuses on three key areas: social, physical, and cognitive engagement. After completing a randomized control trial in 2025, they saw significant improvements in quality of life and a reduction in neuropsychiatric symptoms. The company has partnered with over 50 memory clinics in Germany, and their therapy is now recommended to patients. Being part of the Alzheimer's Moonshot Community has also helped them better understand market dynamics and connect with experts.
Highlights
🧠 Mission and Focus: MindAhead aims to improve quality of life and slow cognitive decline for individuals with mild cognitive impairment and early dementia through a digital behavioral therapy.
📊 Successful Trial: In 2025, they completed their first randomized control trial, showing significant improvements in quality of life and a reduction in neuropsychiatric symptoms.
🌍 Partnerships: MindAhead has partnered with over 50 memory clinics in Germany, with their therapy now recommended to patients.
🤝 Community Impact: Being part of the Alzheimer's Moonshot Community has helped MindAhead connect with fellow founders and experts, deepening their understanding of the market.
Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is available to StartUp Health Members. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit.
👉 Learn more and join today.
